Literature DB >> 1689281

Binding of basic fibroblast growth factor to normal and neovascularized rabbit cornea.

G Soubrane1, J Jerdan, I Karpouzas, N A Fayein, B Glaser, G Coscas, Y Courtois, J C Jeanny.   

Abstract

The labeling pattern of frozen sections of rabbit cornea incubated with radioiodinated basic fibroblast growth factor (bFGF) was investigated in normal corneas and prostaglandin-induced neovascularized corneas by autoradiography followed by image analysis. 125I-bFGF binds to Bowman's, Descemet's, and vascular basement membranes in a dose-dependent manner. The specificity of the binding of bFGF to basement membrane was demonstrated by the following experiments: 1) an excess of unlabeled growth factor displaced the labeling; 2) histones did not modify the labeling; and 3) 2 M NaCl washing and enzymatic treatment with heparitinase prevented binding of labeled growth factor without apparent destruction of the overall structure of the basement membrane. Our results suggest that bFGF binds to the heparan sulfate proteoglycan of basement membranes. Both normal limbal vessels and the newly formed corneal vessels exhibited the same type of labeling but with different intensities, according to the degree of maturation of the new vessels. bFGF binding also is located clearly on the endothelial cells in both types of vessels. This second binding site could correspond to the high affinity receptors on the cell surface and suggests a direct interaction of bFGF with endothelial cells during new vessel formation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1689281

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  11 in total

1.  Characterisation of corneal fibrotic wound repair at the LASIK flap margin.

Authors:  A Ivarsen; T Laurberg; T Møller-Pedersen
Journal:  Br J Ophthalmol       Date:  2003-10       Impact factor: 4.638

2.  Laser photocoagulation for corneal stromal vascularization.

Authors:  V S Nirankari
Journal:  Trans Am Ophthalmol Soc       Date:  1992

Review 3.  Emerging techniques to treat corneal neovascularisation.

Authors:  J Menzel-Severing
Journal:  Eye (Lond)       Date:  2011-10-07       Impact factor: 3.775

Review 4.  Mediators of ocular angiogenesis.

Authors:  Yureeda Qazi; Surekha Maddula; Balamurali K Ambati
Journal:  J Genet       Date:  2009-12       Impact factor: 1.166

Review 5.  Molecular underpinnings of corneal angiogenesis: advances over the past decade.

Authors:  Nizar Saleh Abdelfattah; Mohamed Amgad; Amira A Zayed; Heba Hussein; Nawal Abd El-Baky
Journal:  Int J Ophthalmol       Date:  2016-05-18       Impact factor: 1.779

Review 6.  Corneal neovascularization and the utility of topical VEGF inhibition: ranibizumab (Lucentis) vs bevacizumab (Avastin).

Authors:  William Stevenson; Sheng-Fu Cheng; Mohammad H Dastjerdi; Giulio Ferrari; Reza Dana
Journal:  Ocul Surf       Date:  2012-01-25       Impact factor: 5.033

7.  Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis).

Authors:  Dimitri T Azar
Journal:  Trans Am Ophthalmol Soc       Date:  2006

8.  In situ injury-induced release of basic-fibroblast growth factor from corneal epithelial cells.

Authors:  A P Adamis; B Meklir; N C Joyce
Journal:  Am J Pathol       Date:  1991-11       Impact factor: 4.307

9.  Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin) eye drops against corneal neovascularization.

Authors:  Yanyan Koenig; Felix Bock; Folkert Horn; Friedrich Kruse; Katja Straub; Claus Cursiefen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-05-05       Impact factor: 3.117

Review 10.  Novel aspects of corneal angiogenic and lymphangiogenic privilege.

Authors:  David Ellenberg; Dimitri T Azar; Joelle A Hallak; Faisal Tobaigy; Kyu Yeon Han; Sandeep Jain; Zhongjun Zhou; Jin-Hong Chang
Journal:  Prog Retin Eye Res       Date:  2010-01-25       Impact factor: 21.198

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.